Large Granular Lymphocyte Leukemia
Conditions
Brief summary
The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).
Interventions
DRUGSiltuximab
Siltuximab will be given on day 1 of each cycle. The dose will be 11 mg/kg given over 1 hour by intravenous infusion. Each cycle is three weeks (+-3 days).
Sponsors
H. Lee Moffitt Cancer Center and Research Institute
EUSA Pharma, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study. * Male or female, aged \>/= 18. * Meet the diagnosis criteria of LGLL as below: * a. For a patient with treatment-naive LGLL, peripheral blood needs to have CD3+ CD57+ cells \>400/mm³ or CD8+ cells \>650/mm³, and, evidence for clonal T cell receptor gamma or beta gene rearrangement by PCR needs to be detected in either peripheral blood or bone marrow. * b. For patients with an established diagnosis of LGLL who have been previously treated, multicolor flow cytometry should identify a residual CD3+CD57+CD8+ LGLL population in peripheral blood or bone marrow, and, evidence for clonal T cell receptor gamma or beta gene rearrangement by PCR needs to be detected in either peripheral blood or bone marrow. There is no requirement that peripheral blood absolute clonal CD3+ CD57+ or CD8+ LGLL populations need to reach predetermined minimal value for eligibility since immunosuppressive therapy can significantly decrease LGLL cell count without any impact on neutropenia, anemia or thrombocytopenia which are major causes of morbidity and mortality * Has at least one of the indications for treatment: 1. severe neutropenia less than 500/mm³, OR 2. neutropenia associated with recurrent infection, OR 3. symptomatic anemia with Hemoglobin \< 9 g/dL, OR 4. transfusion-dependent anemia with transfusion needs \>= 1 u per month, OR 5. severe thrombocytopenia \<20,000/mm³, OR 6. thrombocytopenia \<50,000/mm³ with bleeding. * Participant can be treatment-naïve or previously treated for LGLL. * Participant currently receiving therapy must have a wash-out period of ≥ 30 days or 5 elimination half-lives, whichever is longer, prior to study drug administration. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Creatinine clearance (CLCr) ≥15 mL/min. * If a participant has chronic liver disease, Child-Pugh score needs to be either A or B. * For females of reproductive potential: use of highly effective contraception for at least 1 month prior to study drug infusion and agreement to use highly effective contraception during study participation and for an additional 3 months after the last dose of study drug. * For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study participation and for an additional 3 months after the last dose of study drug. Men must agree to not donate sperm during the same period.
Exclusion criteria
* Any active infection requiring systemic therapy, including viral infections such as HIV, Hepatitis B, and/or Hepatitis C. * Current use of methotrexate, cyclophosphamide, or cyclosporine for any medical conditions. * Has coexisting myelodysplastic syndrome (MDS). * Elevated LGL due to viral infection. * Pregnancy or lactation. * Known severe allergic reactions to siltuximab. * At increased risk for Gastrointestinal (GI) perforation, in the opinion of the study investigator. * Received live vaccine 30 days prior to study drug administration or Intend to receive live vaccine during treatment period and within 3 months after last dose of study drug. * Rheumatological conditions such as rheumatoid arthritis (RA) are not
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate | Up to 30 months | Overall response rate is defined as the rate of achieving best response of CR or PR, and will be summarized for participants who have received any dose of study drug |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response Rate (CR) | Up to 30 months | CR rate is defined as the percentage of patients achieving best response of CR. |
| Time to Response (TTR) | Up to 30 months | TTR is defined as time from first dose of study drug to time of meeting criteria for CR or PR, whichever comes first. |
| Duration of Response (DOR) | Up to 30 months | Duration of Response is defined as time from achieving either CR or PR, whichever comes first, to time of progression or starting another LGLL treatment, whichever comes first. |
| Duration of Complete Response | Up to 30 months | Duration of CR is defined as time from achieving CR to time of progression or starting another LGLL treatment, whichever comes first. |
| Time to Complete Response | Up to 30 months | Time to CR is defined as time from first dose of study drug to time of CR |
| Duration of Complete Response with Normalization of PB LGL Count | Up to 30 months | Rate of CR with normalization of PB LGL count is defined as meeting criteria for CR AND a normal PB LGL count ( \<400/mm³ CD3+CD57+ cells or \<650/mm³ CD8+ T cells in PB). |
| Progression Free Survival | Up to 30 months | PFS is defined as time from first dose of study drug to time of disease progression or starting another LGLL treatment, whichever comes first |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORLubomir Sokol, MD, PhD
Moffitt Cancer Center
Outcome results
None listed